Peptris ne ₹70 Crore uthaye! AI se karega bimariyon ka ilaaj, investors ki lagi line

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorAarav Shah|Published at:
Peptris ne ₹70 Crore uthaye! AI se karega bimariyon ka ilaaj, investors ki lagi line
Overview

Arre bhai log, suno! Bengaluru ki Peptris naam ki ek startup ne kamaal kar diya hai. Unhone **₹70 Crore** (yaani $7.7 Million) ka Series A funding round finish kiya hai, jisme IAN Alpha Fund aur Speciale Invest ne leader role play kiya. Yeh paisa unke AI-powered drug discovery programs ko next level par le jaane ke liye hai.

Toh yeh jo ₹70 Crore ka paisa aaya hai na, Peptris ab isko use karega apni AI wali drug discovery ko aur tezi se aage badhane ke liye. Market mein AI ka trend zoron par hai, aur Peptris iska fayda utha kar bimariyon ka ilaaj dhoondhne mein laga hai.

AI ka Dhamaka Drug Discovery mein

Is $7.7 Million ki funding ke saath, Peptris ka main goal hai drug development ke shuruaati stages mein jo problems aati hain, unko solve karna. Normaly, jab koi nayi medicine banti hai toh bahut saare steps hote hain aur end tak sirf kuch hi successful ho paati hain. Peptris ka AI model yeh sab difficulties ko kam karne aur failure rates ghatane mein help karega. Poori duniya mein pharma companies ab AI use kar rahi hain, aur yeh funding usi trend ko follow karti hai.

Market mein Kaisa Hai Scene?

AI drug discovery market 2030 tak $9 Billion tak pahunch sakta hai, aur is saal 2024 mein hi is sector mein 27% zyada investment hui hai, jo ki $3.3 Billion hai. Peptris ka yeh funding round, jismein unhone apne AI models ko aur refine karna hai, bilkul sahi time par aaya hai. Pehle stage mein fail hone wali drugs ki high rates ko kam karna inka focus hai. Yeh company dusri pharma aur biotech firms ke saath milkar kaam karti hai, taaki jaldi aur kam kharch mein nayi medicines develop ho sakein.

Risky Hai Par Potential Bhi Hai

Dekho, drug discovery waise bhi bahut risky business hai. Preclinical stage mein 10% se bhi kam drugs human trials tak pahunch paati hain. AI bahut help kar sakta hai, lekin biological complexities ko samjhna phir bhi ek bada challenge hai. Aur haan, Peptris ka B2B model matlab unka success dusri badi companies ke decisions par bhi depend karta hai. Toh thoda risk toh hai, par agar yeh AI model sahi nikla toh bada impact kar sakta hai.

Aage Kya?

Agley 24 mahine mein Peptris apni iss nayi funding se kuch lead programs ko clinical trials ke liye ready karne par focus karegi aur apna discovery pipeline bhi expand karegi. Naye molecules develop karna aur apni AI, data science aur chemistry teams ko mazboot karna bhi plans mein hai. Sab kuch theek raha toh yeh startup drug discovery mein ek naya maayna layegi.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.